B cell activating factor (BAFF) and BAFF receptors: fakes and facts.
Clin Exp Immunol
; 190(3): 291-292, 2017 12.
Article
em En
| MEDLINE
| ID: mdl-28834574
ABSTRACT
Analysis of B cell activating factor (BAFF) receptors before and after B cell depletion therapy (BCDT) might offer a clue to the understanding of whether some B cell subsets may represent useful biomarkers of biological and clinical responses. Among the BAFF receptors in a cohort of rheumatoid arthritis (RA) patients, the AA have shown, by fluorescence activated cell sorter (FACS) analysis of median fluorescence intensity (MFI), that transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) and B cell maturation antigen (BCMA) do not change, whereas the most important, BAFF receptor 3 (BR3), appears to be decreased before as well as after BCDT in all B cell subsets but not in plasmablasts, the most important subset, depleted by BCDT.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Artrite Reumatoide
/
Linfócitos B
/
Fator Ativador de Células B
/
Receptor do Fator Ativador de Células B
Idioma:
En
Ano de publicação:
2017
Tipo de documento:
Article